The FGF23–Undercarboxylated Osteocalcin Axis in Predialysis Chronic Kidney Disease: Linking Mineral Homeostasis and Bone Turnover
Open Access
- 30 October 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9743
Abstract
Fibroblast growth factor 23 (FGF23) and osteocalcin are involved in mineral and bone metabolism, but their relationship in chronic kidney disease (CKD) remains insufficiently characterized. This cross-sectional study investigated the association between FGF23 and undercarboxylated osteocalcin (Glu-OC) and whether this association persisted after accounting for kidney function. The study included 80 adults: 12 healthy controls and 68 patients with non-dialysis CKD stages G1–G4. Associations were assessed using Spearman correlation, partial correlation adjusted for estimated glomerular filtration rate (eGFR), and complementary multivariable linear regression models. Among patients with CKD, FGF23 was inversely correlated with eGFR (ρ = −0.346, p = 0.004) and Glu-OC (ρ = −0.344, p = 0.004), and positively correlated with serum creatinine (ρ = 0.299, p = 0.013). The inverse association between FGF23 and Glu-OC persisted after adjustment for eGFR (partial ρ = −0.475, p < 0.001). In the multivariable regression models, Glu-OC was inversely associated with FGF23 (standardized β = −0.258, p = 0.024), whereas alkaline phosphatase was positively associated with FGF23 (β = 0.369, p = 0.001). In the model with Glu-OC as the dependent variable, FGF23 (β = −0.266, p = 0.020) and serum calcium (β = −0.366, p = 0.002) were inversely associated with Glu-OC. Significant inverse correlations between FGF23 and Glu-OC were observed in CKD stages G1–G3, but not in stage G4 or the control group. These findings support an association between FGF23 and Glu-OC in non-dialysis CKD and provide a rationale for further investigation of a potential FGF23–Glu-OC axis in CKD-associated mineral and bone disorder (CKD-MBD). Longitudinal and mechanistic studies are needed to clarify the nature and clinical relevance of this association.Keywords
All Related Versions
Funding Information
- Medical University–Pleven, Bulgaria
This publication has 44 references indexed in Scilit:
- The role of fibroblast growth factor 23 in regulation of phosphate balancePediatric Nephrology, 2024
- Current knowledge of bone-derived factor osteocalcin: its role in the management and treatment of diabetes mellitus, osteoporosis, osteopetrosis and inflammatory joint diseasesJournal of Molecular Medicine, 2024
- Regulation of FGF23 Production in OsteocytesCurrent Osteoporosis Reports, 2024
- Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in HumansJournal of Bone and Mineral Research, 2022
- Chronic Kidney Disease—Mineral and Bone Disorders: Pathogenesis and ManagementCalcified Tissue International, 2020
- Vitamin D sterols increase FGF23 expression by stimulating osteoblast and osteocyte maturation in CKD boneBone, 2019
- αKlotho–FGF23 interactions and their role in kidney disease: a molecular insightCellular and Molecular Life Sciences, 2019
- An overview of osteocalcin progressJournal of Bone and Mineral Metabolism, 2016
- Osteocalcin: Skeletal and extra‐skeletal effectsJournal of Cellular Physiology, 2013
- Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standardsOsteoporosis International, 2010